News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Piramal Life Sciences Acquires Assets of Canadian Medtech Firm BioSyntech for Can $3.9 Million
June 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SCRIP -- Piramal Healthcare has signed an agreement to acquire the assets of the Canadian medical technology firm, BioSyntech, for a consideration of Can$3.9 million.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
MORE ON THIS TOPIC
Mergers & acquisitions
Genmab Buys Rising Cancer Star Merus for $8B
September 29, 2025
·
2 min read
·
Tristan Manalac
Podcast
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
September 24, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition
September 22, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Roche Makes Major MASH Move With $3.5B 89bio Buy
September 18, 2025
·
2 min read
·
Tristan Manalac
